Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 4Lymphoid 4Gynecologic 2Gastrointestinal 2Thoracic 1Sarcoma 1Other solid neoplasm 1Genitourinary 1CNS 1Breast 1

Conditions

Osteosarcoma 1

Interventions

Specimen Handling 39Magnetic Resonance Spectroscopy 33Cyclophosphamide 30Doxorubicin 24Biopsy 24pembrolizumab 22Temozolomide 22Radiotherapy 20Radiation 19X-Rays 18Nivolumab 15Vincristine 13Irinotecan 13fludarabine 12Phantoms, Imaging 12Ifosfamide 12Gemcitabine 12atezolizumab 11cabozantinib 10Ipilimumab 9Bevacizumab 9liposomal doxorubicin 8Surgical Procedures, Operative 8Paclitaxel 8Immunoglobulin G 8Etoposide 8Dactinomycin 7Carboplatin 7palbociclib 6olaparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blood Component Removal × Sarcoma × 90 days × Clear all
NCT07428993 2026-05-19

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

St. Jude Children's Research Hospital

Phase 2 Recruiting
41 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡